Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | CETP | P11597 | 11/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15745638 | 0.88 | NPC1 (0.66) | NPC1RAB9AMAPTTP53CETP | |
| SCHEMBL11446660 | 0.86 | NPC1 (0.64) | NPC1RAB9AMAPTTP53CETP | |
| SCHEMBL9681997 | 0.81 | NPC1 (0.71) | NPC1RAB9AMAPTTP53CETP | |
| SCHEMBL14266186 | 0.79 | MAPT (0.67) | NPC1RAB9AMAPTTP53CETP | |
| SCHEMBL19440714 | 0.79 | NPC1 (0.57) | NPC1RAB9AMAPTTP53CETP | |
| SCHEMBL11160763 | 0.78 | NPC1 (0.56) | NPC1RAB9AMAPTTP53CETP | |
| SCHEMBL11167498 | 0.78 | NPC1 (0.56) | NPC1RAB9AMAPTTP53CETP | |
| SCHEMBL28331595 | 0.78 | NPC1 (0.77) | NPC1RAB9AGFERMAPTTP53 | |
| SCHEMBL18593330 | 0.78 | NPC1 (0.52) | NPC1RAB9AGFERMAPTTP53 | |
| SCHEMBL8926190 | 0.75 | NPC1 (0.59) | NPC1RAB9AMAPTTP53CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-01-25 | — | — | US | disclosed |
| US-9783494-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783494-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170216229-A1 | GLUCAGON ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170216229-A1 | GLUCAGON ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20150087680-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-03-26 | — | — | US | disclosed |
| US-20150087680-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-03-26 | — | — | US | disclosed |
| US-8907103-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8907103-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030029-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | NPC1 830/4885RAB9A 2162/4885GFER 1762/4885 |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | NPC1 830/4885RAB9A 2162/4885GFER 1762/4885 |
| US-20170216229-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | NPC1 887/4885RAB9A 2260/4885GFER 1794/4885 |
| US-20190099391-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | NPC1 887/4885RAB9A 2260/4885GFER 1794/4885 |
| US-11352321-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | NPC1 830/4885RAB9A 2162/4885GFER 1762/4885 |
| US-20150087680-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | NPC1 830/4885RAB9A 2162/4885GFER 1762/4885 |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | NPC1 830/4885RAB9A 2162/4885GFER 1762/4885 |
| US-10221130-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | NPC1 887/4885RAB9A 2260/4885GFER 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.